Radium targets for cyclotron production of Ac-225 in view of targeted alpha therapy
Targeted alpha therapy using the radionuclide
Ac-225 has shown remarkable benefit in clinical trials to patients
suffering from various cancer types. Currently most Ac-225 is
produced from a few sources of Th-229 existing worldwide.
However, the total amount available is only sufficient for a few
thousand patient doses. Given a projected demand that is several
orders of magnitude higher, alternative paths for the production of
Ac-225 must be developed. We have been investigating the route
using the Ra-226(p,2n)Ac-225 reaction.
KELLERBAUER Alban;
MALMBECK Rikard;
DE ALMEIDA CARRAPIÇO Carlos;
JAJCISINOVA Erika;
ELOIRDI Rachel;
LEBEDA O.;
MORGENSTERN Alfred;
2023-12-13
SPRINGER
JRC135865
1619-7070 (online),
https://link.springer.com/article/10.1007/s00259-023-06333-x,
https://publications.jrc.ec.europa.eu/repository/handle/JRC135865,
DOI: 10.1007/s00259-023-06333-x (online),
Additional supporting files
| File name | Description | File type | |
|---|
